(Q47852326)

6 February 2018

title

Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression (English)

1 reference

6 February 2018

author name string

Paulo R Shiroma

1

1 reference

6 February 2018

C Sophia Albott

2

1 reference

6 February 2018

Brian Johns

3

1 reference

6 February 2018

Paul Thuras

4

1 reference

6 February 2018

Joseph Wels

5

1 reference

6 February 2018

Kelvin O Lim

6

1 reference

6 February 2018

publication date

25 June 2014

1 reference

6 February 2018

The International Journal of Neuropsychopharmacology

published in

1 reference

6 February 2018

volume

17

1 reference

6 February 2018

issue

11

1 reference

6 February 2018

page(s)

1805-1813

1 reference

6 February 2018

The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Altered prefrontal dopaminergic function in chronic recreational ketamine users

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Psychiatric safety of ketamine in psychopharmacology research

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

A synaptic model of memory: long-term potentiation in the hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

21 January 2018

Ketamine use: a review

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Executive dysfunction and the course of geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

The post-anesthesia recovery score revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Acute Effects of Ketamine on Memory Systems and Psychotic Symptoms in Healthy Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Acute and chronic effects of ketamine upon human memory: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

The depression-executive dysfunction (DED) syndrome and response to antidepressants: a meta-analytic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Subtle effects of ketamine on memory when administered following stimulus presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Ketamine--can chronic use impair memory?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Neurocognitive effects after brief pulse and ultrabrief pulse unilateral electroconvulsive therapy for major depression: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Ketamine in adults: what emergency physicians need to know about patient selection and emergence reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

The electroconvulsive therapy controversy: evidence and ethics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Schizophrenia, ketamine and cannabis: evidence of overlapping memory deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Serial infusions of low-dose ketamine for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Subtypes of memory dysfunction associated with ECT: characteristics and neurobiological bases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

Differential effects of two NMDA receptor antagonists on cognitive--behavioral performance in young nonhuman primates II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

inferred from DOI database lookup

7 January 2021

based on heuristic

Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS)

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

inferred from DOI database lookup

7 January 2021

based on heuristic

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145714001011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1017/S1461145714001011

1 reference

6 February 2018

1 reference

6 February 2018